COMPANY PROFILE

LB Pharmaceuticals

Clinical-stage biopharmaceutical company developing novel therapies for schizophrenia and other neuropsychiatric disorders

New York City, United StatesFounded 2015Biotech & Life Sciences

Valuation $1–2.5B Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About LB Pharmaceuticals

LB Pharmaceuticals is a clinical-stage biopharmaceutical company based in New York City, developing novel therapies for schizophrenia, bipolar depression and other neuropsychiatric disorders. The company's lead candidate, LB-102, is a novel methylated derivative of amisulpride designed to improve the safety and efficacy profile of the benzamide antipsychotic class, with a focus on treating the positive and negative symptoms of schizophrenia. The company was founded in 2015 and has progressed LB-102 through Phase 1 into Phase 2 clinical development. It completed an initial public offering on the Nasdaq in September 2025, raising approximately $285 million, and continues to expand its programmes in neuropsychiatry.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: New York City, United States
Employees: 1
Open positions: 2
Dealroom signal: 60.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
PRIVATE PLACEMENT VCOther financing	Feb 2026	$100M	—	Balyasny Asset Management · Pivotal BioVenture Partners · TCGX · Spruce Street Capital	↗
IPOOther financing	Sep 2025	$285M	$381M	Undisclosed	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Growth	Margin
2026	—	—
2025	—	—
2024	—	—
2023	—	—
2022	—	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

LB Pharmaceuticals website traffic

Latest recorded traffic for LB Pharmaceuticals is 5.1K monthly website visits, up 45.7% over the last three months.

Latest monthly visits5.1K 3-month web change+45.7%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Director, Statistical Programming (Pharma/Biotech Experience Required)New York, New York, United States, Northern America, Americas · Data Science & Engineering · Aug 7, 2026 Director, Clinical and Pharmacovigilance QualityNew York, New York, United States, Northern America, Americas · Other · Jul 20, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SSSecondWave SystemsDeveloping a novel, ultrasound-based wearable neuromodulation platform	Minneapolis, United States	Operational	19	$17M	$28M
FUFunPepFunPep is an Industry-university collaboration bioventure company	Ibaraki, Japan	Operational
AIArterial Health InternationalProvides clinical diagnostic tests for a comprehensive evaluation of cardiovascular disease risk factors	Atlanta, United States	Operational
LYLysoclearPremium laboratory research services for biotechnology and pharmaceutical companies, specializing in ocular toxicology and structural biology	Lafayette, United States	Operational
TBTAGCyx BiotechnologiesCreating candidate compounds for high-performance nucleic acid drugs with high affinity and specificity for target molecules using our proprietary nucleic acid basic technology	Tokyo, Japan	Acquired
ANAmygdala NeuroscienceAmygdala's mission is to address the growing unmet need associated with substance use disorder by discovering, developing and commercializing safe and effective pharmacotherapies to treat and prevent addiction	Palo Alto, United States	Operational
ATAnHeart TherapeuticsPrecision medicine biopharmaceutical company leveraging expertise in clinical research and development and product registration focusing initially on oncology products	Huangpu, China	Acquired
CBContraria BiotechDevelops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics	Siena, Italy	Operational